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A B S T R A C T
Introduction: Retigabine (RTG) is now approved in Europe and the US for the adjunctive treatment of
partial-onset seizures in adults with epilepsy. To support submissions to EU reimbursement authorities,
we explored its efﬁcacy and tolerability relative to selected antiepileptic drugs (AEDs).
Methods: A systematic review was conducted to identify placebo-controlled trials of RTG and selected
AEDs approved for use in a similar position in the management pathway of partial epilepsy
(eslicarbazepine acetate [ESL], lacosamide [LCM], pregabalin [PGB], tiagabine [TGB] and zonisamide
[ZNS]). Using conventional and network meta-analyses as appropriate, we report efﬁcacy and
tolerability outcomes for each AED versus placebo and the performance of RTG relative to other AEDs.
Results: Twenty studies met the inclusion criteria: three each for RTG, ESL, LCM, TGB and ZNS; ﬁve for
PGB. Comparisons comprised 1–5 studies per AED. In the network meta-analysis, RTG was not found to
be different from the other AEDs for responder rate (maintenance period), seizure freedom (maintenance
period and double-blind period), withdrawals due to adverse events, and incidences of ataxia, dizziness,
fatigue and nausea. Differences between RTG and other AEDs were found for a few comparisons, which
did not reveal any trends: RTG was associated with a lower responder rate than PGB during the double-
blind period, higher withdrawal rate due to any reason than ESL and a higher incidence of somnolence
than TGB.
Conclusions: Findings suggest that the risk/beneﬁt for RTG is similar to that for comparator AEDs.
However, results should be interpreted in the context of the limitations of the analyses.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Retigabine (RTG, international non-proprietary name) is the
ﬁrst potassium channel opener to be approved for the treatment of
epilepsy. It is indicated in Europe for the adjunctive treatment of
partial-onset seizures, with or without secondary generalization,
in adults with epilepsy. RTG is also approved in other countries,
including the US (under the US adopted name of ezogabine), where
it is approved for the adjunctive treatment of partial-onset
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http://dx.doi.org/10.1016/j.seizure.2012.07.011thus stabilizing the resting membrane potential, RTG offers a novel
treatment option for patients who have not previously attained an
adequate response to other antiepileptic drugs (AEDs).1
When a new drug for the adjunctive treatment of partial-onset
seizures becomes available, information on its efﬁcacy and
tolerability proﬁle relative to other treatments may be required
to inform the decision-making process for payers in the absence of
head-to-head data. To support submissions to EU reimbursement
authorities, a systematic review was conducted to compare the
efﬁcacy and tolerability of RTG relative to other selected
adjunctive treatments approved for partial-onset seizures in
adults with epilepsy.
The AEDs selected as appropriate comparators for RTG
(eslicarbazepine acetate [ESL], lacosamide [LCM], pregabalin
[PGB], tiagabine [TGB] and zonisamide [ZNS]) were those approved
for use in Europe, over approximately the last 10 years, as
adjunctive (but not mono-) therapy for partial epilepsy. RTG
would be used in a similar position in the management pathway
for partial-onset seizures as these comparator AEDs, and thesevier Ltd. All rights reserved.
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considered as alternatives to RTG in pharmacy formularies. AEDs
such as carbamazepine, lamotrigine, levetiracetam, oxcarbazepine,
sodium valproate and topiramate, which are licensed for mono-
therapy in patients with partial-onset seizures, are also licensed for
adjunctive use; however these well-established agents are
generally used earlier in the adjunctive treatment pathway than
the agents selected for this study and were therefore not
considered appropriate comparators.2
The objective of this review was to evaluate the efﬁcacy and
tolerability of RTG relative to the selected drugs for the purposes of
providing comparative data for EU reimbursement authorities.
Using the best available data from randomized controlled trials,
meta-analysis and indirect comparisons were employed for
analyses.
The efﬁcacy and tolerability of each drug compared with
placebo and/or comparator AEDs were assessed for the following
predeﬁned outcomes: proportion of patients responding to
treatment (50% reduction in seizure frequency), proportion of
patients seizure-free over the treatment period, proportion of
withdrawals (due to adverse events [AEs] and for any reason) and
proportion of patients reporting speciﬁed AED-related AEs
(ataxia, dizziness, fatigue, nausea and somnolence).3
2. Methods
The protocol used for the present review is available on
www.yhec.co.uk/docs/retigabine_protocol.pdf.
2.1. Eligibility criteria
Randomized (head-to-head or placebo-controlled) studies of
adjunctive therapy that used either a parallel group design or a
crossover design, in which data from the ﬁrst treatment period
could be treated as a parallel study, were eligible for inclusion.
Eligible studies included a treatment period at target dose
(maintenance phase) of 8 weeks, with a prospective baseline
period of 4 weeks, and reported change in seizure frequency and
treatment withdrawal as outcomes. The population of interest was
adults (18 years) with partial-onset epileptic seizures who had
failed to respond adequately to previous AEDs (not controlled by
one or more AEDs). Studies reported in any language and published
in full or as abstracts or conference presentations were eligible for
consideration for inclusion in the analysis.
2.2. Searches and study selection
All searches were conducted on 28th June 2010. The following
databases were searched over the time periods speciﬁed to identify
eligible studies: MEDLINE and MEDLINE In-process (OvidSP)
(1950–2010/June week 3); EMBASE (1980–2010/week 25);
Cochrane Database of Systematic Reviews (2010 Issue 6/2);
Cochrane Central Register of Controlled Trials (2010 Issue 6/2);
Database of Abstracts of Reviews of Effects (2010 Issue 6/2); Health
Technology Assessment Database (2010 Issue 6/2); Science
Citation Index (1899–2010/June 26th); and Conference Proceed-
ings Citation Index – Science (1990–2010/June 26th). Other
databases and internet resources were searched for all records
available on the date of searching: National Guidelines Clearing-
house; National Library of Guidelines; National Horizon Scanning
Centre; ClinicalTrials.gov; Current Controlled Trials Register; WHO
International Clinical Trials Registry Platform; TRIP Database;
OAIster; European Medicines Agency; and US Food and Drug
Administration. Searches were limited to human studies; no
methodological search ﬁlters were used and no date (within
speciﬁed ranges) or language limits were applied. After removal ofduplicates, records were screened for relevance and selected full-
text articles assessed for eligibility; no abstracts or conference
presentations were selected. In addition to data identiﬁed from the
literature searches, unpublished data from four trial and regulatory
reports made available by the study co-sponsors were included
(GlaxoSmithKline [2009]. RTG: Summary of Clinical Efﬁcacy
[module 2.7.3] European Marketing Authorisation Application;
Valeant Pharmaceuticals [2009]. Clinical Study Reports CSR-2065-
205, CSR-301 and VRX-RET-E22-302).
2.3. Data collection
Details of the study, participant characteristics, intervention,
analysis, outcomes and AEs were extracted from the selected
publications by one researcher and independently checked by at
least one other researcher. The quality of randomized controlled
trials was assessed using seven questions that focus on the
following methodological aspects: appropriate randomization,
adequate concealment of treatment allocation, comparability of
groups at baseline, blinding procedures, unexpected imbalances in
dropouts, measured versus reported outcomes, and inclusion of an
intent-to-treat analysis.4
2.4. Data analysis
The outcomes evaluated included the proportion of patients
responding to treatment (deﬁned as 50% responder rate, the
proportion of patients who showed at least 50% reduction in
seizure frequency relative to baseline), proportion of patients
seizure-free over the treatment period, proportion of withdrawals
(separate analyses for withdrawals due to AEs and for any reason)
and proportion of patients reporting any of ﬁve speciﬁed AED-
related AEs identiﬁed by the Cochrane Epilepsy Group3: ataxia,
dizziness, fatigue, nausea and somnolence. When considering
studies that measured responder rate and seizure freedom over
different periods, separate analyses were undertaken for the
efﬁcacy outcomes for the ﬁxed-dose maintenance phase of the
treatment period (post-titration) and the full double-blind period
(titration and maintenance).
AEDs were compared using two statistical methods. In a
conventional meta-analysis (CMA), outcome measures reported
for the treatment arm(s) were compared within trials against those
for the comparator; comparisons were also conducted using
pooled data from all the eligible trials for each of the selected AEDs.
In a network meta-analysis (NMA), outcome measures from the
treatment arm(s) were compared with those from the placebo arm,
and each AED was compared with each other AED via the network.
A CMA of comparisons between treatment and placebo was
initially undertaken using the Mantel–Haenszel and DerSimonian
and Laird methods, employing Stata statistical software: Release
11 (StataCorp LP, College Station, TX). Pooled effect estimates as
odds ratios (ORs) and relative risks were calculated using both
ﬁxed- and random-effects models; results described here are the
ORs (and their associated 95% conﬁdence intervals [CI]) from ﬁxed-
effects model analyses. Statistical heterogeneity was assessed
using the Q statistic in conjunction with the I-squared (I2) statistic5
(I2 value 50%, low; >50% to <75%, moderate; 75%, high
heterogeneity). The I2 statistic measures the extent of inconsis-
tency among the results of different studies, and is interpreted as
the approximate proportion of total variation in study estimates
that is due to heterogeneity rather than sampling error.5 Results of
the CMA are presented in forest plots; data from random-effects
model analyses and the weights contributed by each study to the
pooled analysis for each AED are presented for information
purposes. Potential publication bias was examined through funnel
plot inspection6 but was considered uninformative given the small
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estimates from the CMA as Z-scores were considered statistically
signiﬁcant at P  0.05.
A hierarchical Bayesian NMA was then undertaken using
WinBUGS Version 14 (MRC Biostatistics Unit, Cambridge, UK). A
ﬁxed-effects approach to data synthesis was used, utilizing a ﬁxed-
effects logistic regression model with parameters estimated by
Markov Chain Monte Carlo simulation. A random-effects model
was also applied initially but, following convergence failure due to
the small number of studies, is not presented. Results from the
NMA are presented here as mean ORs and 95% credible intervals
(95% CrI).
Inconsistency between the CMA and NMA was assessed by
comparing the OR from the NMA with that from the CMA; evidence
was assumed to be inconsistent if the OR from the NMA did not lie
within the 95% CI of the corresponding OR from the CMA.
When placebo-controlled trials included multiple treatment
arms that evaluated different doses of an AED, the events and
patient numbers from the different treatment arms were initially
combined to create a single, pooled comparison of drug versus
placebo. Additional analyses were undertaken to take into
consideration clinically relevant dose ranges; i.e. to exclude doses
that were included in the trials but were not subsequently licensed
(for LCM, 600 mg/day). The results presented here refer to the
maintenance dose ranges approved in Europe (for LCM, 200–
400 mg/day). Further analyses were undertaken to evaluate
outcomes for individual doses of an AED but are not reported here.
Here, the performance of each AED relative to placebo and of
RTG relative to other AEDs is reported.
3. Results
3.1. Studies
In total, 4387 records were identiﬁed for potential inclusion,
and of these, 175 reports were assessed in detail for eligibility
(Fig. 1). Following removal of duplicates and screening for
eligibility, 20 trials met the eligibility criteria, all of which were
placebo-controlled: three studies each for RTG,7–9 ESL,10–12
LCM,13–15 TGB,16–18 and ZNS19–21; and ﬁve studies for PGB.22–26
The main reason for excluding reports (based on assessment
of full-text papers) was that the data were reported in full
elsewhere.
For each study, summary characteristics are presented in
Table 1, and a quality assessment is presented in Table S1.
3.2. Efﬁcacy outcomes
3.2.1. 50% responder rate during the ﬁxed-dose maintenance period
Drug comparisons comprised one to three studies per AED:
LCM, RTG and ZNS were each evaluated in three studies; ESL in two
studies; and TGB in one study. None of the included studies
reported this outcome for PGB.
In the CMA, there was a statistically signiﬁcant difference in the
50% responder rate for all AEDs compared with placebo
(P < 0.001), with the exception of TGB (P = 0.122) (Fig. 2a).
Moderate heterogeneity was observed among RTG/placebo com-
parisons (I2 = 60.9%). All other comparisons displayed low hetero-
geneity (I2 = 0%).
Based on the results of the NMA, there was no evidence that RTG
performed any better or worse than other AEDs with respect to this
outcome (Table 2).
3.2.2. 50% responder rate during the double-blind period
Comparisons comprised two to ﬁve studies per AED: PGB was
evaluated in ﬁve studies, RTG in three studies, and ESL and TGB intwo studies each. None of the studies included reported this
outcome for LCM or ZNS.
In the CMA, there was a statistically signiﬁcant difference in the
50% responder rate for all AEDs compared with placebo
(P < 0.0001) (Fig. 2b). Heterogeneity was low among most of
the drug–placebo comparisons (I2 = 0%), with the exception of the
ﬁve studies that evaluated PGB, which displayed moderate
heterogeneity (I2 = 63.0%).
Based on the results of the NMA, RTG was comparable with the
other AEDs, with the exception of PGB. There was a smaller effect
for RTG than for PGB for this outcome (OR [CrI]: 0.65 [0.41–0.96])
(Table 2).
3.2.3. Seizure freedom during the ﬁxed-dose maintenance period
Nine studies reported seizure freedom during the maintenance
phase: three each for LCM and RTG, two for ESL and one for TGB.
None of the included PGB or ZNS studies reported this outcome.
Although TGB was considered for initial inclusion in the NMA, no
patients in the placebo arm of the trial achieved seizure freedom
during the maintenance period (zero events). TGB was excluded
from this analysis because of problems with statistical conver-
gence of the ﬁxed-effect model.
Of the four AEDs evaluated in the CMA, only RTG was
statistically signiﬁcantly different from placebo (OR [95% CI]:
2.53 [1.11–5.76], P = 0.026) (Fig. 3a). Where estimable (2
studies), low heterogeneity was observed (I2 = 0%). In the NMA,
based on the ORs and their CrIs, RTG was not notably different from
ESL and LCM with respect to seizure freedom assessed over the
maintenance period (Table 2).
3.2.4. Seizure freedom during the double-blind period
A total of eight studies reported seizure freedom assessed over
the full double-blind period: three for RTG, two each for PGB and
ZNS, and one for ESL. This outcome was not reported in the
included LCM or TGB studies. Due to sparse data (zero events in the
placebo arm of the ESL study), model convergence of the ﬁxed-
effect model could not be attained. As such, ESL was not evaluated
in the NMA for this outcome.
No statistically signiﬁcant effects on seizure freedom assessed
over the double-blind period were evident from the CMA of
any drug-versus-placebo comparison (Fig. 3b). Low heterogeneity
(I2 = 0%) was observed for comparisons for which heterogeneity
could be estimated (2 studies).
However, based on the results of the NMA, only RTG appeared
to be more effective than placebo in achieving seizure freedom
over the double-blind period (OR [95% CrI]: 3.74 [1.10–10.93])
but was not notably different from other AEDs (Table 2).
3.3. Study withdrawals
3.3.1. Withdrawals due to AEs
Study withdrawal data were available for 19 of the 20 studies:
PGB was evaluated in 5 studies, ESL, LCM, RTG and TGB were each
evaluated in 3 studies, and ZNS was evaluated in 2 studies.
From the CMA, all treatments resulted in a statistically
signiﬁcant higher rate of withdrawals due to AEs compared with
placebo (P < 0.002) (Fig. 4a). Overall, low levels of heterogeneity
were observed among all comparisons of drug versus placebo, with
the exception of the three TGB studies, which displayed moderate
heterogeneity (I2 = 61.2%).
Based on the NMA, RTG was not notably any better or worse
than the other AEDs in terms of withdrawals due to AEs (Table 2).
3.3.2. Withdrawals due to any reason
Of the 20 studies included, 19 reported numbers of patients
completing the trial, from which overall total withdrawals could be
Records identified through
database searching
(n = 4380)
Records after duplicates
removed
(n = 2329)
Records screened
(n = 2329)
Full-text articles assessed
for eligibility
(n = 175)
Records excluded
(n = 2154)
Full-text articles
excluded
(n = 150)
Reports included in
quantitative synthesis 
(network meta-analysis)
(n = 25)
Trials included in 
quantitative synthesis 
(network meta-analysis)
(n = 20)
Additional records identified
through other sources
(n = 7)
Fig. 1. Flow diagram of the study identiﬁcation process.
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two for ZNS.
From the CMA, all treatments led to a statistically signiﬁcant
higher withdrawal rate than placebo (P = 0.041 to P < 0.0001),
with the exception of ESL (P = 0.297) (Fig. 4b).
Heterogeneity for the comparison of ESL versus placebo was
moderate (I2 = 73.0%), whereas all other comparisons displayed
low heterogeneity (I2 = 0%).
Based on the NMA, RTG was associated with a higher OR for
overall withdrawals than ESL (OR [95% CrI]: 1.91 [1.18–2.89]), but
was not associated with a markedly different withdrawal rate
compared with other AEDs (Table 2).
3.4. Tolerability outcomes
3.4.1. Ataxia
Eight studies reported data for ataxia: four for PGB, two for RTG
and one each for LCM and ZNS. All of these studies were evaluated
in the CMA, but due to zero count data and subsequent problems
with statistical convergence, ZNS was excluded from the NMA.
In the CMA, PGB, RTG and ZNS, but not LCM, were associated
with statistically signiﬁcant greater reporting of ataxia compared
with placebo (P = 0.047 to P < 0.001) (Fig. 5a). It should be noted,
however, that the ZNS and LCM comparisons each comprised onlyone study. Where estimable (2 studies), low levels of heteroge-
neity were observed for all comparisons (I2 = 0%).
Based on the results of the NMA, RTG was not associated with a
difference in the reporting of ataxia compared with other AEDs
(Table 2).
3.4.2. Dizziness
Eighteen studies reported data on dizziness: ﬁve for PGB, three
for ESL, LCM and RTG, and two for TGB and ZNS. The results from
the CMA of dizziness were statistically signiﬁcant for all drug
comparisons versus placebo (ranging from P = 0.003 to
P < 0.0001), that is, all AEDs were associated with greater
reporting of dizziness compared with placebo (Fig. 5b). Low levels
of heterogeneity were observed for all comparisons (I2 values of 0%
in the majority of comparisons). Based on the results of the NMA,
RTG was not associated with a difference in the reporting of
dizziness compared with the other AEDs (Table 2).
3.4.3. Fatigue
Seven studies reported data on fatigue: two for LCM and RTG,
and one each for ESL, PGB and ZNS.
The results from the CMA of fatigue indicated that, of each of the
AEDs analysed, only RTG was associated with a statistically
signiﬁcant higher incidence of fatigue compared with placebo
Table 1
Studies included in the meta-analyses.
Study Population Interventions and numbers
randomized to placebo
and treatment
Duration of intervention
Retigabine/ezogabine (RTG) studies
Brodie (2010)7 Adults aged 18–75 y; localization-related
epilepsy refractory to stable doses of 1–3
AEDs; 4 qualifying seizures per 28 d without
a seizure-free period of >21 d during the
baseline period
Placebo (n = 179)
RTG 600 mg/d (n = 181)
RTG 900 mg/d (n = 179)
Baseline period: 8 w
Titration period: 4 w
Maintenance period: 12 w
Double-blind period: 16 w
French (2011)8 Adults aged 18–75 y; treatment-resistant
focal epilepsy characterized by simple partial
or complex partial-onset seizures, with/
without secondary generalization; 4 partial
seizures per 28 d over baseline period;
receiving stable doses of 1–3 AEDs for
1 month prior to screening
Placebo (n = 152)
RTG 1200 mg/d (n = 154)
Baseline period: 8 w
Titration period: 6 w
Maintenance period: 12 w
Double-blind period: 18 w
Porter (2007)9 Adults aged 16–70 y; inadequately controlled
partial-onset seizures (simple partial with an
observable motor component or complex
partial, with/without secondary
generalization); 4 partial-onset seizures per
month during baseline period, no 30-d
seizure-free period; stable doses of 1–2 AEDs
Placebo (n = 96)
RTG 600 mg/d (n = 100)
RTG 900 mg/d (n = 95)
RTG 1200 mg/d (n = 106)
Baseline period: 8 w
Titration period: 8 w
Maintenance period: 8 w
Double-blind period: 16 w
Eslicarbazepine acetate (ESL) studies
Ben-Menachem (2010)10 Adults aged 18 y; diagnosed with simple or
complex partial-onset seizures, with/without
secondary generalization, for 12 months
prior to screening; 4 partial-onset seizures
in the two 4-w periods prior to screening and
during each of the two 4-w periods of the
baseline phase; receiving stable doses of 1–3
concomitant AEDs for 2 months prior to
screening
Placebo (n = 100)
ESL 400 mg/d (n = 96)
ESL 800 mg/d (n = 101)
ESL 1200 mg/d (n = 98)
Baseline period: 8 w
Titration period: 400/800 mg
groups = start with full
maintenance dose; 1200 mg
group = 800 mg QID for 2 w,
then full 1200 mg
maintenance dose
Maintenance period: 12 to 14 w
Double-blind period: 14 w
Elger (2009)11 Adults aged 18 y; simple or complex partial
seizures with/without secondary
generalization for 12 months prior to
screening; 4 partial-onset seizures in the
two 4-w periods of the baseline phase; no
seizure-free interval >21 consecutive days;
receiving stable doses of 1–2 AEDs for
2 months prior to screening
Placebo (n = 102)
ESL 400 mg/d (n = 100)
ESL 800 mg/d (n = 98)
ESL 1200 mg/d (n = 102)
Baseline period: 8 w
Titration period: 2 w
(All patients started at 400 mg;
800 mg group = full dose by
the end of week 1; 1200 mg
group = full dose by end of week 2)
Maintenance period: 12 w
Double-blind period: 18 w
including 4 w down-titration
Gil-Nagel (2009)12 Adults aged 18 y; simple or complex partial
seizures (with/without secondary
generalization) for 12 months prior to
screening; 4 partial-onset seizures in the
two 4-w periods prior to screening and
during each of the two 4-w baseline periods;
receiving stable doses of 1–2 concomitant
AEDs for 2 months prior to screening
Placebo (n = 88)
ESL 800 mg/d (n = 85)
ESL 1200 mg/d (n = 80)
Baseline period: 8 w
Titration period: 2 w
Maintenance period: 12 w
Double-blind period: 18 w
including 4 w taper
Lacosamide (LCM) studies
Ben-Menachem (2007)13 Adults aged 18–65 y; simple or complex
partial-onset seizures, with/without
secondary generalization; partial-onset
seizures for at least the last 2 y despite
therapy with 2 AEDs; during the baseline
period, 4 partial-onset seizures per 28 d on
average, no seizure-free period >21 d;
receiving stable doses of 1–2 AEDs in the 4 w
before enrolment and during the baseline
period
Placebo (n = 97)
LCM 200 mg/d (n = 107)
LCM 400 mg/d (n = 108)
LCM 600 mg/d (n = 106)
Baseline period: 8 w
Titration period: 6 w (weekly
increments of 100 mg/d)
Maintenance period: 12 w
Double-blind period: 18 w
Chung (2010)14 Adults aged 16–70 y; partial-onset seizures,
with/without secondary generalization; 2-y
history of partial onset seizures despite
treatment with 2 AEDs (concurrently or
sequentially); currently experiencing 4
partial-onset seizures per 28 d, with no
seizure-free period >21 d during the 8 w prior
to and during the baseline period; receiving
stable doses of 1–3 AEDs in the 4 w prior to
enrolment and during baseline
Placebo (n = 104)
LCM 400 mg/d (n = 204)
LCM 600 mg/d (n = 97)
Baseline period: 8 w
Titration period: 6 w
Maintenance period: 12 w
Double-blind phase: 18 w
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Halasz (2009)15 Adults aged 16–70 y; partial-onset seizures
for at least the preceding 2 y despite prior
therapy with 2 AEDs; on average, 4
partial-onset seizures per 28 d, with no
seizure-free period longer than 21 d during
the 8-w period before enrolment and during
the baseline period; stable doses of 1–3 AEDs
in the 4 w prior to enrolment and during the
baseline period
Placebo (n = 163)
LCM 200 mg/d (n = 163)
LCM 400 mg/d (n = 159)
Baseline period: 8 w
Titration period: 4 w
Maintenance period: 12 w
Double-blind period: 18 w
including 2 w taper
Pregabalin (PGB) studies
Arroyo (2004)22 Adults aged 18 y; partial seizures (simple,
complex, or secondarily generalized tonic–
clonic) and failed 1 AED at the maximum
tolerated dose; 3 partial seizures in the
month before screening; 6 partial seizures
and not seizure-free for any 4-w period
during the 8-w period before randomization;
receiving 1–3 AEDs at tolerated, clinically
relevant doses; concurrent AED maintained
at the same dose during the study
Placebo (n = 97)
PGB 150 mg/d (n = 99)
PGB 600 mg/d (n = 92)
Baseline period: 8 w
Titration period: titrated to
full dose by days 4 (placebo
and 150 mg/d) and 8 (600 mg/d)
Maintenance period: 11 w
Double-blind period: 12 w
Beydoun (2005)23 Adults aged 18 y; inadequately controlled
partial-onset seizures; 6 partial-onset
seizures during the baseline period, with no
28-d seizure-free period, while on stable
doses of 1–3 AEDs; 2 AEDs at maximally
tolerated doses failed
Placebo (n = 98)
PGB 600 mg/d BID (n = 104)
PGB 600 mg/d TID (n = 111)
Baseline period: 8 w
Titration period: 1 w
Maintenance period: 11 w
Double-blind period: 12 w
Elger (2005)24 Adults aged 18 y; diagnosis of epilepsy with
partial seizures; had not previously received
PGB; 4 partial seizures during the baseline
period with no 28-d seizure-free period;
currently receiving 1–3 AEDs
Placebo (n = 73)
PGB 600 mg/d (n = 131)
PGB 150–600 mg/d (n = 137)
Baseline period: 6 w
Titration period: placebo and
600 mg/d groups = none; PGB
varied dose group = start on
150 mg/d (75 mg BID) for ﬁrst
2 w, and increased to 300 mg/d
for next 2 w (then 300–600 mg/d)
Maintenance period: 12 w
Double-blind period: 12 w
French (2003)25 Adults aged 12–70 y; 3 partial seizures in
the month prior to screening and 6 partial
seizures in the 8 w between screening and
baseline; refractory to 2 AEDs at maximally
tolerated doses; currently receiving 1–3 AEDs
Placebo (n = 100)
(PGB 50, not evaluable
in present report mg/d, n = 88)
PGB 150 mg/d (n = 88)
PGB 300 mg/d (n = 90)
PGB 600 mg/d (n = 89)
Baseline period: 8 w
Titration period: none (start on
randomized dose)
Maintenance period: 12 w
Double-blind period: 12 w
Lee (2009)26 Adults 18 y; diagnosis of partial seizures
(simple, complex or secondarily generalized
tonic–clonic); 4 seizures that had occurred
over 2 d during a 6-w baseline period; no
28-d seizure-free period; 1 AED at the
maximally tolerable dose tried; taking 1–3
AEDs at a clinically relevant dose
Placebo (n = 59)
PGB 600 mg/d (n = 119)
Baseline period: 6 w
Titration period: 6 w
Maintenance period: 6 w
Double-blind period: 13 w
(including 1 w taper)
Tiagabine (TGB) studies
Kalviainen (1998)16 Adults aged 16–75 y; partial seizures (six in
the previous 8 w); 8 partial seizures during
the baseline period while on a stable regimen
of 1–3 AEDs; no seizure-free interval of >4 w
during the baseline period
Placebo (n = 77)
TGB 30 mg/d (n = 77)
Baseline period: 12 w
Titration period: 6 w
Maintenance period: 12 w
Double-blind period: 22 w
including 4 w taper
Sachdeo (1997)17 Adults and teenagers aged 12–75 y; diagnosis
of complex partial seizures with/without
secondary generalization; 6 complex partial
seizures during the 8-w period before
screening and 1 complex partial seizure
within each of the two 4-w segments within
the 8-w period; treated with a stable regimen
of 1–3 AEDs
Placebo (n = 107)
TGB 32 mg/d BID (n = 106)
TGB 32 mg/d QID (n = 105)
Baseline period: 8 w
Titration period: 4 w
Maintenance period: 8 w
Double-blind period: 12 w
Uthman (1998)18 Patients aged 12–77 y; 6 complex partial
seizures in the 8 w preceding the screening
visit (each of the two 4-w segments
containing 1 complex partial seizure);
receiving a stable regimen of 1–3 hepatic
enzyme-inducing AEDs
Placebo (n = 91)
TGB 16 mg/d (n = 61)
TGB 32 mg/d (n = 88)
TGB 56 mg/d (n = 57)
Baseline period: 12 w
Titration period: 4 w
Maintenance period: 12 w
Double-blind period: 20 w
(including 4 w discontinuation)
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Table 1 (Continued )
Study Population Interventions and numbers
randomized to placebo
and treatment
Duration of intervention
Zonisamide (ZNS) studies
Brodie (2005)19 Patients aged 12 y; partial seizures, with/
without secondary generalization
unsatisfactorily controlled despite a stable
regimen of 1–3 AEDs
Placebo (n = 120)
ZNS 100 mg/d (n = 57)
ZNS 300 mg/d (n = 56)
ZNS 500 mg/d (n = 118)
Baseline period: 12 w
Titration period: 6 w
Maintenance period: 18 w
Double-blind period: 24 w
Sackellares (2004)20 Adults aged 17–65 y; history of partial
seizures refractory to current AED therapy;
4 complex partial seizures per month; no
more than eight generalized tonic–clonic, or
tonic–clonic seizures per month; receiving 1–
2 of the following AEDs: phenytoin,
carbamazepine, phenobarbital, primidone
Placebo (n = 74)
ZNS 400–600 mg/d (n = 78)
Baseline period: 8–12 w
Titration period: 4 w
Maintenance period: 8 w
Double-blind period: 12 w
Schmidt (1993)21 Adults aged 18–59 y; complex partial
seizures; an average of 4 complex partial
seizures per month during the 4 months
preceding the baseline period, in spite of
therapeutic plasma concentrations of
standard AEDs
Placebo (n = 68)
ZNS 6 mg/kg/d to achieve
20–30 mg/ml (n = 71)
Baseline period: 8–12 w
Titration period: 4 w
Maintenance period: 8 w
Double-blind period: 12 w
All studies were randomized, double-blind placebo-controlled studies. AED, anti-epileptic drug; BID, twice daily; d, day; QID, once daily; TID; three times daily; w, weeks; y,
years.
M. Martyn-St James et al. / Seizure 21 (2012) 665–678 671(OR [95% CI]: 3.78 [2.16–6.62], P < 0.001) (Fig. 5c). However,
between-trial heterogeneity was observed for the RTG compar-
isons (I2 = 72.6%). Based on the results of the NMA, RTG was not
associated with a difference in the reporting of fatigue compared
with other AEDs (Table 2).
3.4.4. Nausea
Eleven studies reported data on nausea: three for LCM and for
RTG, two for ESL and ZNS and one for TGB.
The results from the CMA of nausea showed a statistically
signiﬁcant effect of ESL (P = 0.004) and LCM (P = 0.003) compared
with placebo. No statistically signiﬁcant effects were observed for
other drug comparisons with placebo in the CMA (Fig. 5d). Where
estimable (2 studies), low levels of heterogeneity were observed
(I2 values of 0–37.5%). Based on the results of the NMA, RTG was
not associated with a difference in the reporting of nausea
compared with other AEDs (Table 2).
3.4.5. Somnolence
Sixteen studies reported data on somnolence: ﬁve for PGB,
three for ESL and RTG, two for LCM and ZNS, and one for TGB.
The results from the CMA of somnolence showed statistically
signiﬁcant effects of PGB (P < 0.001), RTG (P < 0.001) and ZNS
(P = 0.003) compared with placebo. No other statisticallyTable 2
Results of the network meta-analyses comparing retigabine with ﬁve comparator drug
Comparator drug
Outcome Eslicarbazepine acetate Lacosa
50% responder rate – maintenance phase 1.34 (0.80–2.13) 1.28 (0
50% responder rate – double-blind phase 1.02 (0.57–1.67) NA 
Seizure freedom – maintenance phase 1.13 (0.17–3.75) 1.09 (0
Seizure freedom – double-blind phase ND NA 
Withdrawals due to AEs 0.87 (0.38–1.67) 1.03 (0
Withdrawals due to any reason 1.91 (1.18–2.89) 1.31 (0
Ataxia NA 1.30 (0
Dizziness 1.12 (0.56–1.96) 1.07 (0
Fatigue 3.92 (0.93–10.50) 2.11 (0
Nausea 0.41 (0.10–1.01) 0.69 (0
Somnolence 1.72 (0.92–2.90) 1.59 (0
AEs, adverse events; NA, not available (data for comparison not available from studies r
data with zero count events in some treatment arms).
Data are presented as odds ratios (ORs) with 95% credible intervals (CrIs). The greater 
Numbers in bold type indicate notable differences between comparator drugs (95% Crsigniﬁcant effects were observed for comparisons in the CMA
(Fig. 5e). Where estimable (2 studies), low levels of heterogeneity
were observed (I2 values of 0–41.4%). Based on the results of the
NMA, RTG was not associated with a difference in the reporting of
somnolence compared with other AEDs, with the exception of TGB,
with RTG being associated with a greater reporting of somnolence
(OR [95% CrI]: 2.38 [1.03–7.14]) (Table 2).
3.5. Comparison of data from the CMA and NMA
In the assessment of inconsistency between the CMA and NMA,
all ORs for placebo comparisons from the NMA were within the
95% CIs of those from the CMA, indicating that the two analysis
techniques were consistent.
4. Discussion
This analysis was undertaken to support submissions to
reimbursement authorities, by providing data to facilitate com-
parison of the efﬁcacy and tolerability of RTG with other selected
AEDs that may be used in a similar position in the management
pathway of adults with partial-onset seizures. A rigorously
designed and conducted, systematic process was used to identify
studies meeting the inclusion criteria for this review. As nos (odds ratios and 95% credible intervals).
mide Pregabalin Tiagabine Zonisamide
.84–1.87) NA 0.83 (0.29–3.23) 0.91 (0.58–1.52)
0.65 (0.41–0.96) 0.63 (0.33–1.30) NA
.14–3.52) NA ND NA
2.59 (0.29–9.94) ND 0.76 (0.20–6.25)
.53–1.83) 0.97 (0.51–1.66) 1.12 (0.60–2.38) 0.74 (0.34–1.82)
.79–2.02) 1.42 (0.91–2.13) 1.09 (0.65–1.89) 1.35 (0.79–2.44)
.18–4.25) 1.01 (0.33–2.49) NA ND
.58–1.81) 0.98 (0.56–1.61) 1.45 (0.80–2.94) 0.88 (0.35–2.63)
.78–6.64) 2.25 (0.32–7.07) NA 1.45 (0.55–5.00)
.29–1.39) NA 1.14 (0.42–4.35) 1.10 (0.47–3.23)
.69–3.07) 0.94 (0.55–1.52) 2.38 (1.03–7.14) 0.52 (0.21–1.54)
eviewed); ND, non-determinable (problems with model convergence due to sparse
the observed OR, the greater the probability of the event occurring.
Is do not cross 1).
Fig. 2. Conventional meta-analysis forest plots for 50% responder rate. Plots indicate the observed I2 values and associated P-value for heterogeneity from the conventional
meta-analysis, along with the effect estimates and 95% CIs. Asterisks indicate an insufﬁcient number of studies in the comparison to undertake heterogeneity testing.
Diamond shape indicates overall treatment effect with 95% CIs. CI, conﬁdence interval; OR, odds ratio; M–H, Mantel–Haenszel (ﬁxed effects); D + L, DerSimonian and Laird
(random effects).
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Fig. 3. Conventional meta-analysis forest plots for seizure freedom. Plots indicate the observed I2 values and associated P-value for heterogeneity from the conventional meta-
analysis, along with the effect estimates and 95% CIs. Asterisks indicate an insufﬁcient number of studies in the comparison to undertake heterogeneity testing. Diamond
shape indicates overall treatment effect with 95% CIs. CI, conﬁdence interval; OR, odds ratio; M–H, Mantel–Haenszel (ﬁxed effects); D + L, DerSimonian and Laird (random
effects).
M. Martyn-St James et al. / Seizure 21 (2012) 665–678 673published trials compared AEDs directly, comparisons between
drugs were conducted using indirect analyses of data from 20
eligible, placebo-controlled studies. For each AED included, the
presented data represent the combined analysis of results pooled
over the approved dose range, that is, the therapeutic range
available to clinicians. From the analysis of pooled AED trials, theefﬁcacy and tolerability of RTG appeared to be broadly comparable
with the other selected AEDs.
In the absence of randomized controlled trials comparing AEDs
directly, pooled effects from an NMA may provide useful
information to inform treatment decisions.27 In this review,
results from individual placebo-controlled studies were pooled
Fig. 4. Conventional meta-analysis forest plots for study withdrawals. Plots indicate the observed I2 values and associated P-value for heterogeneity from the conventional
meta-analysis, along with the effect estimates and 95% CIs. Asterisks indicate an insufﬁcient number of studies in the comparison to undertake heterogeneity testing.
Diamond shape indicates overall treatment effect with 95% CIs. CI, conﬁdence interval; OR, odds ratio; M–H, Mantel–Haenszel (ﬁxed effects); D + L, DerSimonian and Laird
(random effects).
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Fig. 5. Conventional meta-analysis forest plots for selected adverse events. Plots indicate the observed I2 values and associated P-value for heterogeneity from the
conventional meta-analysis, along with the effect estimates and 95% CIs. Asterisks indicate an insufﬁcient number of studies in the comparison to undertake heterogeneity
testing. Diamond shape indicates overall treatment effect with 95% CIs. CI, conﬁdence interval; OR, odds ratio; M–H, Mantel–Haenszel (ﬁxed effects); D + L, DerSimonian and
Laird (random effects).
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pooling multiple studies, meta-analysis can help to identify a
common estimate of the effect size across the included studies. For
the clinician, an NMA adds a further dimension to treatment
comparisons. Rather than basing treatment decisions on trials that
have evaluated the same treatment compared with placebo, an
NMA allows comparisons of different treatments directly with
each other using statistical inference. However, the estimates for
ORs for active drug–placebo comparisons may differ between the
CMA and NMA. The main reason for this is that the Bayesian
estimate (NMA) is the mean of a simulated posterior distribution
for the ORs; this distribution is skewed, so the mean is pulled away
from the centre (median) of the distribution. In contrast with the
Bayesian estimate, the Mantel–Haenszel estimate (CMA) is formed
as the weighted mean of individual estimates of the OR from the
component trials; each of these estimates corresponds to the
centre (median) of what would be the Bayesian estimate for that
trial. Both methods are statistically valid for estimating the
location of a distribution, and they tend to differ more when the CIs
are wide and when the ORs are far from 1. In the present analysis,
no inconsistencies were observed between the NMA and CMA.
Although these statistical techniques are useful in providing
comparative data, they also have recognized limitations that
should be taken into consideration when interpreting results.28,29
Results are susceptible to potential bias from a number of sources,
including selective reporting and heterogeneity among included
studies.28 The analysis included unpublished data for RTG that
were made available for this investigation by the study sponsor.
For other AEDs, the analysis was limited to the data that could be
extracted from published sources. It is therefore uncertain whether
a publication bias may exist for these other AEDs. Whilst efforts
were made to perform a meta-analysis on comparable studies,
potential between-trial differences in design and patient char-
acteristics cannot be discounted and should be taken into
consideration when interpreting the results from this review.
For example, studies evaluating ﬂexible dosing (which is reﬂective
of clinical practice) were identiﬁed for PGB, TGB and ZNS. In
contrast, only ﬁxed-dose studies (conducted for drug registration
purposes) were identiﬁed for ESL, LCM and RTG. In addition, the
speed of titration of an AED may impact on tolerability, with slower
titration rates associated with better tolerability.30 This may
introduce bias in the comparison of tolerability outcomes for AEDs
with different titration rates. Trials of the older agents (PGB, TGB
and ZNS) generally included fewer patients, recruited from fewer
centres, than the trials of the newer agents (RTG, ESL and LCM). The
precision of the pooled effect estimates from these trials should
also be considered when interpreting results. Factors such as
participants’ age, the proportion of men and women in the study,
disease severity among participants, and concomitant treatments,
are possible sources of clinical heterogeneity that should also be
considered.
Moderate and high levels of between-trial heterogeneity were
observed in some of the CMA comparisons for some AEDs. For the
PGB studies reviewed for responder rate, the observed heteroge-
neity may be explained by the inclusion of one trial in which the
time at target dose was shorter than in the other trials.25 For the
ESL studies reviewed for withdrawal rate, the observed heteroge-
neity may be partly explained by the inclusion of one trial, which
reported a larger number of withdrawals due to protocol
violation, compared with the other trials included in the analysis.9
The moderate levels of heterogeneity that were observed among
RTG studies measuring responder rate during the ﬁxed-dose
maintenance period may be explained by the contribution of one
trial, which reported a high proportion of participant with-
drawals, and in which the maintenance phase was shorter than in
the other RTG trials.8The methodological issues raised by indirect comparisons and
their relevance for comparing AEDs in adjunctive therapy for
partial epilepsy have been explored recently.31 Variables that are
also considered as factors inﬂuencing efﬁcacy estimates include
the treatment period used to calculate efﬁcacy endpoints, the year
in which the trial was conducted, and the method used to calculate
responder rates.31 The number of trials contributing to each
outcome of interest for each AED should also be considered. It is
recommended that the results from an NMA should also be
interpreted alongside empirical observations.27 Clinicians should
consider these factors, in addition to those discussed previously,
when interpreting results from an NMA. In the light of all available
evidence, clinicians will need to decide whether one treatment can
be considered a better option than another for the population or
individual of interest.
In addition to the limitations of the techniques used, the
ﬁndings from this review are also limited by the small number of
eligible studies that were identiﬁed for each agent. Heterogeneity
was therefore difﬁcult to assess in some instances, and random-
effect models proved difﬁcult to ﬁt in the NMA for some outcomes.
The small number of included studies also resulted in large
credible intervals for a number of outcomes/AEDs in the NMA. In
addition, a few observations were not consistent with clinical
experience. For example, ataxia was reported only in one of three
LCM studies. Ataxia is not generally observed as an AE with this
drug.13–15 However, in the NMA, the frequency of ataxia appeared
similar with LCM and PGB, which contrasts with the expectation
that this AE would be reported more frequently with PGB.22–26 The
results for outcomes that were not reported by all of the trials
evaluating a speciﬁc AED should therefore be interpreted with
caution. The relatively short treatment periods that were
evaluated in the included trials, coupled with variations in the
characteristics of the patient populations recruited, also limits
the generalizability of the ﬁndings from this review. Furthermore,
the speciﬁed AEs evaluated in this review were central nervous
system (CNS)-related events that are commonly related to AEDs as
a class. Other, non-CNS-related AEs, including those that might
be drug-speciﬁc, were not evaluated. The ﬁndings on comparative
tolerability of the AEDs evaluated in this review must therefore
be interpreted with caution.
The agents selected for comparison with RTG were chosen on
the basis that they were the most recently launched agents
licensed for adjunctive treatment but not monotherapy, and
therefore had comparable positioning to RTG in the treatment
pathway for partial-onset seizures. Although this strategy exclud-
ed some frequently used adjunctive AEDs, such as levetiracetam
and topiramate, the AEDs included were those that reimbursement
authorities were likely to require comparative data for when
considering reimbursement for RTG. Although the performance of
RTG was broadly comparable with the other selected AEDs, some
differences were observed. Treatment with RTG was associated
with a lower responder rate than PGB during the double-blind
period (OR [95% CrI]: 0.65 [0.41–0.96]), and a higher rate of
withdrawal due to any reason, compared with ESL (OR [95% CrI]:
1.91 [1.18–2.89]). RTG was also associated with higher reporting of
somnolence than TGB (OR [95% CrI]: 2.38 [1.03–7.14]). Given that
no adjustments for were made to correct for the occurrence of false
positives that could emerge from evaluating multiple endpoints
and treatment group comparisons, such differences might be
expected. For the PGB and ESL studies reviewed for responder rate
and withdrawals, respectively, in the NMA, moderate levels of
between-study heterogeneity were observed (I2 = 63% and 73%) in
the CMA (possible explanations for this have been discussed
earlier), whereas low heterogeneity was observed for the RTG
studies (0%). This limits the validity of indirect comparisons for
PGB and ESL with RTG within the NMA. For TGB, the outcome for
M. Martyn-St James et al. / Seizure 21 (2012) 665–678 677somnolence was based on one study only, so may not be
representative of the wider patient population treated with
this AED.
AEDs other than those evaluated in this review have been
compared using indirect methods. Otoul et al. reported that
levetiracetam was more effective in terms of responder rate than
gabapentin and lamotrigine, and equally well tolerated.32 The
reviewers also observed that levetiracetam had a signiﬁcantly
lower withdrawal rate than topiramate and oxcarbazepine,
with comparable efﬁcacy.32 The clinical comparability of oxcar-
bazepine, lamotrigine, topiramate, gabapentin, PGB, levetirace-
tam, TGB, ZNS, ESL and LCM in partial epilepsy has also been
evaluated recently by Costa et al.33 These reviewers observed that
topiramate and levetiracetam were most effective in reducing
seizure frequency, whereas gabapentin was less effective in
comparison with the other AEDs evaluated. The reviewers also
reported that tolerability, as indicated by higher withdrawal rates,
was poorer with oxcarbazepine and topiramate, whereas gaba-
pentin and levetiracetam were better tolerated than the other
AEDs assessed but that, overall, the frequency of the most
common AEs was comparable between the AEDs. These reviewers
concluded that the relatively small magnitude of differences
observed between AEDs did not allow a deﬁnitive conclusion to be
reached about which AED(s) had superior clinical effectiveness.
The limitations of indirect comparisons were considered to
contribute to this uncertainty, and the authors suggested that
clinical decision-making in partial epilepsy probably depends
more on aspects such as individual patient characteristics and
pharmacoeconomics than on available evidence from randomized
controlled trials.
The limited number of eligible studies for some of the AEDs
evaluated in this review, coupled with the uncertainty surround-
ing some of the efﬁcacy and tolerability effect estimates, may
explain why few differences were detected between RTG and
other AEDs that have other mechanisms of action. Moreover, the
lack of impact of mechanism of action on drug efﬁcacy, and a
common pattern of outcomes across different AEDs in clinical
studies of refractory epilepsy, has been reported elsewhere.34,35 It
has been suggested that the introduction of AEDs with novel
mechanisms of action has not substantially improved the efﬁcacy
of treatment, at least in part because the design of trials for
regulatory purposes dictates that new agents are tested in
patients with refractory seizures who are currently receiving
one or more established AEDs.34–36 Against this background of
anti-seizure activity, potentially through multiple mechanisms of
action, it is unlikely that adding a further AED will have a
signiﬁcant impact across the population studied, although each
new AED is likely to have some impact in some patients.37
5. Conclusions
In conclusion, on the basis of the outcomes from the indirect
comparisons, and considering the limitations and caveats outlined,
our ﬁndings suggest that RTG provides similar risks and beneﬁts as
adjunctive therapy for patients with partial-onset seizures with or
without secondary generalization compared with the other AEDs
studied. On the basis of the data discussed here, RTG was
recommended for use for this indication in adults aged 18 years
and older with epilepsy in England and Wales by the National
Institute for Health and Clinical Excellence (NICE) and in Scotland
by the Scottish Medicines Consortium (SMC). The NICE recom-
mendation is speciﬁcally for use when previous treatment with a
deﬁned list of AEDs has not provided an adequate response, or has
not been tolerated, whereas the SMC recommendation is for use in
patients with refractory epilepsy. Whilst these indirect compar-
isons should contribute to the total body of evidence available, it isrecommended that they be considered in combination with direct
evidence, and that randomized head-to-head studies be undertak-
en to permit a direct assessment of the comparative strengths and
weaknesses of different AEDs in particular patient populations.
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